Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?

Frankel, Jeffrey; Staskin, David; Varano, Susann; Newman, Diane K; Gregg, Steven G; Owens-Grillo, Janet

Frankel, Jeffrey; Staskin, David; Varano, Susann; Newman, Diane K; Gregg, Steven G; Owens-Grillo, Janet.

Afiliación

Frankel J; Seattle Urology Research Center, Seattle, WA, USA.
Staskin D; Tufts University School of Medicine, Boston, MA, USA.
Varano S; Clinical Research Consulting, Milford, CT, USA.
Newman DK; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Gregg SG; National Association for Continence, Charleston, SC, USA.
Owens-Grillo J; Sumitomo Pharma America, Inc. (formerly Urovant Sciences, Inc.), Marlborough, MA, USA.

J Comp Eff Res ; 12(9): CER, 2023 09.

Article en En | MEDLINE | ID: mdl-37586052

Asunto(s)

Vejiga Urinaria Hiperactiva; Humanos; Vejiga Urinaria Hiperactiva/tratamiento farmacológico; Calidad de Vida; Resultado del Tratamiento; Micción

Palabras clave

beta-3 adrenergic receptor agonist; bladder leaks; clinical meaningfulness; lay summary; overactive bladder; patient-reported outcomes; plain language summary; quality of life; trial; urinary frequency; urinary urgency; vibegron

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vejiga Urinaria Hiperactiva Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Humans Idioma: En Revista: J Comp Eff Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google